001     143430
005     20240229112552.0
024 7 _ |a 10.1101/gr.242453.118
|2 doi
024 7 _ |a pmid:30846532
|2 pmid
024 7 _ |a 1054-9803
|2 ISSN
024 7 _ |a 1088-9051
|2 ISSN
024 7 _ |a 1549-5469
|2 ISSN
024 7 _ |a altmetric:56660957
|2 altmetric
037 _ _ |a DKFZ-2019-01018
041 _ _ |a eng
082 _ _ |a 540
100 1 _ |a Zhivagui, Maria
|b 0
245 _ _ |a Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans.
260 _ _ |a Cold Spring Harbor, NY
|c 2019
|b Laboratory Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1555066704_5713
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Humans are frequently exposed to acrylamide, a probable human carcinogen found in commonplace sources such as most heated starchy foods or tobacco smoke. Prior evidence has shown that acrylamide causes cancer in rodents, yet epidemiological studies conducted to date are limited and, thus far, have yielded inconclusive data on association of human cancers with acrylamide exposure. In this study, we experimentally identify a novel and unique mutational signature imprinted by acrylamide through the effects of its reactive metabolite glycidamide. We next show that the glycidamide mutational signature is found in a full one-third of approximately 1600 tumor genomes corresponding to 19 human tumor types from 14 organs. The highest enrichment of the glycidamide signature was observed in the cancers of the lung (88% of the interrogated tumors), liver (73%), kidney (>70%), bile duct (57%), cervix (50%), and, to a lesser extent, additional cancer types. Overall, our study reveals an unexpectedly extensive contribution of acrylamide-associated mutagenesis to human cancers.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Ng, Alvin W T
|b 1
700 1 _ |a Ardin, Maude
|b 2
700 1 _ |a Churchwell, Mona I
|b 3
700 1 _ |a Pandey, Manuraj
|b 4
700 1 _ |a Renard, Claire
|b 5
700 1 _ |a Villar, Stephanie
|b 6
700 1 _ |a Cahais, Vincent
|b 7
700 1 _ |a Robitaille, Alexis
|b 8
700 1 _ |a Bouaoun, Liacine
|b 9
700 1 _ |a Heguy, Adriana
|b 10
700 1 _ |a Guyton, Kathryn Z
|b 11
700 1 _ |a Stampfer, Martha R
|b 12
700 1 _ |a McKay, James
|b 13
700 1 _ |a Hollstein, Monica
|0 P:(DE-He78)f3bec70c95e9e3dce0f39d54b3843118
|b 14
|u dkfz
700 1 _ |a Olivier, Magali
|b 15
700 1 _ |a Rozen, Steven G
|b 16
700 1 _ |a Beland, Frederick A
|b 17
700 1 _ |a Korenjak, Michael
|b 18
700 1 _ |a Zavadil, Jiri
|b 19
773 _ _ |a 10.1101/gr.242453.118
|g Vol. 29, no. 4, p. 521 - 531
|0 PERI:(DE-600)1483456-x
|n 4
|p 521 - 531
|t Genome research
|v 29
|y 2019
|x 1549-5469
909 C O |o oai:inrepo02.dkfz.de:143430
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)f3bec70c95e9e3dce0f39d54b3843118
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENOME RES : 2017
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b GENOME RES : 2017
920 1 _ |0 I:(DE-He78)C016-20160331
|k C016
|l Genetische Veränderungen bei der Karzinogenese
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C016-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21